NCT04661020

CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Clinical Trial for the Efficacy and Safety of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Detailed description

This study is indicated for patients with CD19+ newly diagnosed high-risk large B-cell lymphoma. This study is an investigator-initiated, single-center, single-arm phase II clinical trial of rituximab, lenalidomide, and zanubrutinib (ZR2) with Sequential CAR-T cell as first-line therapy for newly diagnosed high-risk LBCL. Primary objective is to explore the efficacy and also safety.

Conditions

• Large B-Cell Lymphoma (LBCL)

Interventions

Type	Name	Description
DRUG	CD19 CAR-T cells	Each subject receive CD19 CAR T-cells by intravenous infusion

Timeline

• Start date: 2020-12-03
• Primary completion: 2026-12-20
• Completion: 2026-12-20
• First posted: 2020-12-09
• Last updated: 2026-04-07

Locations

1 site across 1 country: China